Cargando…

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

PURPOSE: Rearranged during transfection (RET) gene rearrangement is a well-known driver event in non–small cell lung cancer (NSCLC). Pralsetinib is a selective inhibitor of RET kinase and has shown efficacy in oncogenic RET-altered tumors. This study evaluated the efficacy and safety of expanded acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Youngkyung, Jung, Hyun Ae, Park, Sehhoon, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Lee, Se-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582535/
https://www.ncbi.nlm.nih.gov/pubmed/37218138
http://dx.doi.org/10.4143/crt.2023.403
_version_ 1785122353127096320
author Jeon, Youngkyung
Jung, Hyun Ae
Park, Sehhoon
Sun, Jong-Mu
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
Lee, Se-Hoon
author_facet Jeon, Youngkyung
Jung, Hyun Ae
Park, Sehhoon
Sun, Jong-Mu
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
Lee, Se-Hoon
author_sort Jeon, Youngkyung
collection PubMed
description PURPOSE: Rearranged during transfection (RET) gene rearrangement is a well-known driver event in non–small cell lung cancer (NSCLC). Pralsetinib is a selective inhibitor of RET kinase and has shown efficacy in oncogenic RET-altered tumors. This study evaluated the efficacy and safety of expanded access program (EAP) use of pralsetinib in pretreated, advanced NSCLC patients with RET rearrangement. MATERIALS AND METHODS: Patients who received pralsetinib as part of the EAP at Samsung Medical Center were evaluated through a retrospective chart review. The primary endpoint was overall response rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 guidelines. Secondary endpoints were duration of response, progression-free survival (PFS), overall survival (OS), and safety profiles. RESULTS: Between April 2020 and September 2021, 23 of 27 patients were enrolled in the EAP study. Two patients who were not analyzed due to brain metastasis and two patients whose expected survival was within 1 month were excluded from the analysis. After a median follow-up period of 15.6 months (95% confidence interval [CI], 10.0 to 21.2), ORR was 56.5%, the median PFS was 12.1 months (95% CI, 3.3 to 20.9), and the 12-month OS rate was 69.6%. The most frequent treatment-related adverse events (TRAEs) were edema (43.5%) and pneumonitis (39.1%). A total of 8.7% of patients experienced extra-pulmonary tuberculosis. TRAEs with a common grade of three or worse were neutropenia (43.5%) and anemia (34.8%). Dose reduction was required in nine patients (39.1%). CONCLUSION: Pralsetinib presents a clinical benefit when used in patients with RET-rearranged NSCLC, consistent with a pivotal study.
format Online
Article
Text
id pubmed-10582535
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-105825352023-10-19 Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement Jeon, Youngkyung Jung, Hyun Ae Park, Sehhoon Sun, Jong-Mu Ahn, Jin Seok Ahn, Myung-Ju Park, Keunchil Lee, Se-Hoon Cancer Res Treat Original Article PURPOSE: Rearranged during transfection (RET) gene rearrangement is a well-known driver event in non–small cell lung cancer (NSCLC). Pralsetinib is a selective inhibitor of RET kinase and has shown efficacy in oncogenic RET-altered tumors. This study evaluated the efficacy and safety of expanded access program (EAP) use of pralsetinib in pretreated, advanced NSCLC patients with RET rearrangement. MATERIALS AND METHODS: Patients who received pralsetinib as part of the EAP at Samsung Medical Center were evaluated through a retrospective chart review. The primary endpoint was overall response rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 guidelines. Secondary endpoints were duration of response, progression-free survival (PFS), overall survival (OS), and safety profiles. RESULTS: Between April 2020 and September 2021, 23 of 27 patients were enrolled in the EAP study. Two patients who were not analyzed due to brain metastasis and two patients whose expected survival was within 1 month were excluded from the analysis. After a median follow-up period of 15.6 months (95% confidence interval [CI], 10.0 to 21.2), ORR was 56.5%, the median PFS was 12.1 months (95% CI, 3.3 to 20.9), and the 12-month OS rate was 69.6%. The most frequent treatment-related adverse events (TRAEs) were edema (43.5%) and pneumonitis (39.1%). A total of 8.7% of patients experienced extra-pulmonary tuberculosis. TRAEs with a common grade of three or worse were neutropenia (43.5%) and anemia (34.8%). Dose reduction was required in nine patients (39.1%). CONCLUSION: Pralsetinib presents a clinical benefit when used in patients with RET-rearranged NSCLC, consistent with a pivotal study. Korean Cancer Association 2023-10 2023-05-22 /pmc/articles/PMC10582535/ /pubmed/37218138 http://dx.doi.org/10.4143/crt.2023.403 Text en Copyright © 2023 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jeon, Youngkyung
Jung, Hyun Ae
Park, Sehhoon
Sun, Jong-Mu
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
Lee, Se-Hoon
Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
title Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
title_full Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
title_fullStr Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
title_full_unstemmed Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
title_short Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
title_sort expanded access program pralsetinib in advanced non–small cell lung cancer with rearranged during transfection (ret) gene rearrangement
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582535/
https://www.ncbi.nlm.nih.gov/pubmed/37218138
http://dx.doi.org/10.4143/crt.2023.403
work_keys_str_mv AT jeonyoungkyung expandedaccessprogrampralsetinibinadvancednonsmallcelllungcancerwithrearrangedduringtransfectionretgenerearrangement
AT junghyunae expandedaccessprogrampralsetinibinadvancednonsmallcelllungcancerwithrearrangedduringtransfectionretgenerearrangement
AT parksehhoon expandedaccessprogrampralsetinibinadvancednonsmallcelllungcancerwithrearrangedduringtransfectionretgenerearrangement
AT sunjongmu expandedaccessprogrampralsetinibinadvancednonsmallcelllungcancerwithrearrangedduringtransfectionretgenerearrangement
AT ahnjinseok expandedaccessprogrampralsetinibinadvancednonsmallcelllungcancerwithrearrangedduringtransfectionretgenerearrangement
AT ahnmyungju expandedaccessprogrampralsetinibinadvancednonsmallcelllungcancerwithrearrangedduringtransfectionretgenerearrangement
AT parkkeunchil expandedaccessprogrampralsetinibinadvancednonsmallcelllungcancerwithrearrangedduringtransfectionretgenerearrangement
AT leesehoon expandedaccessprogrampralsetinibinadvancednonsmallcelllungcancerwithrearrangedduringtransfectionretgenerearrangement